Novo Nordisk shares rose 19% over the past month following FDA approval and launch of oral Wegovy, the first GLP-1 agonist pill for obesity and cardiovascular risk reduction. Management expects the oral formulation to expand global obesity treatment penetration and offset near-term international market headwinds.